The standard therapy for acute myeloid leukemia (AML) includes the drugs cytarabine and daunorubicin. However, despite this treatment, many patients succumb to the disease.
AC220 is an investigational drug which works by blocking certain targets on cancer cells (enzymes called “receptor tyrosine kinases,” or RTKs). It appears to work best in patients with AML who have mutations in the FLT3-ITD gene. In prior studies, some patients with AML achieved remission after receiving AC220 alone.
The purpose of this study is to find the highest dose of AC220 that can be given safely with cytarabine and daunorubicin in patients with AML who have not yet received treatment.